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Pharmacological chaperones are small molecules that bind to pro-
teins and stabilize them against thermal denaturation or proteolytic
degradation, as well as assist or prevent certain protein–protein as-
semblies. These activities are being exploited for the development of
treatments for diseases caused by protein instability and/or aberrant
protein–protein interactions, such as those found in certain forms of
cancers and neurodegenerative diseases. However, designing or dis-
covering pharmacological chaperones for specific targets is challeng-
ing because of the relatively featureless protein target surfaces, the
lack of suitable chemical libraries, and the shortage of efficient high-
throughput screening methods. In this study, we attempted to ad-
dress all these challenges by synthesizing a diverse library of small
molecules that mimic protein α-helical secondary structures com-
monly found in protein–protein interaction surfaces. This was accom-
panied by establishing a facile “on-bead” high-throughput screening
method that allows for rapid and efficient discovery of potential
pharmacological chaperones and for identifying novel chaperones/
inhibitors against a cancer-associated protein, myeloid cell leukemia 1
(MCL-1), and a Parkinson disease-associated protein, α-synuclein. Our
data suggest that the compounds and methods described here will
be useful tools for the development of pharmaceuticals for complex-
disease targets that are traditionally deemed “undruggable.”
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The majority of drugs on the market today target proteins withdefined small-molecule binding sites, including enzymes
(47%), transmembrane receptors (34%), and transmembrane
channels and transporters (11%) (1). These drugs are usually
small molecules that compete with the target protein’s natural
substrates, which are typically also small molecules, for binding
in the active site or substrate-binding site, for example. However,
some of the most pressing and devastating diseases involve
proteins that do not possess these natural binding sites, such as
those involved in protein–protein interactions (PPIs), associated
with many cancers, and protein-misfolding, associated with most
neurodegenerative diseases (2–5). For these reasons, there is
considerable interest in the design and synthesis of molecules
that can modulate PPIs and/or protein stability.
In this article, we show a class of ligands that are intended to
stabilize the protein in vitro and in vivo and, as such, are potential
pharmacological chaperones. Pharmacological chaperones are
small molecules that bind to proteins and stabilize them against
thermal denaturation or proteolytic degradation, as well as assisting
or preventing certain protein–protein assembly (6–8). Designing
pharmacological chaperones against traditionally “undruggable”
protein surfaces relies heavily on the availability of three-
dimensional structures of the proteins of interests, which are used
for the identification of “hotspots” and for the design of ligand
mimetic structures (9–11). A variety of classes of compounds have
been shown to be effective pharmacological chaperones, including
cofactor mimetics (12), catalytic inhibitors (13), ligand mimetics
(14), stabilized helical peptides (15–17), and small-molecule
secondary structure-mimetics (18, 19). However, discovering
pharmacological chaperones for specific targets is challenging for
several reasons, including the characteristics of the protein surfaces,
the lack of suitable chemical libraries, and the shortage of efficient
high-throughput screening (HTS) methods (20, 21). Here, we de-
scribe the design and synthesis of a diverse library of small mole-
cules that mimic α-helical secondary structures. The synthetic
method is highly accessible, and the resulting compounds showed
good aqueous solubility and cell permeability. We then describe the
establishment of a facile “on-bead” HTS method that allows for
rapid and efficient discovery of potential pharmacological chaper-
ones. Finally, we successfully demonstrate the feasibility of our
strategy by identifying myeloid cell leukemia 1 (MCL-1) inhibitors
targeting α-helix-groove interaction as well as α-synuclein stabilizers
targeting helix–helix interfaces.
Results and Discussion
Design of a Triazine-Piperazine-Triazine Scaffold as α-Helix Mimetics.
α-Helices are involved in mediating many PPIs in which short
α-helical peptide segments spanning two to three helical turns
play a key role as a recognition motif, and side chains at i, i + 3 or
i + 4, and i + 7 are often crucial for PPIs (Fig. 1A). Because
α-helix-mediated PPIs are involved in various cellular signaling
pathways, there have been tremendous efforts to develop mol-
ecules that can mimic helical peptide structures to modulate such
interactions (18, 22). These include stabilized helical peptides
(15–17, 23) and peptidomimetic foldamers (24–29). Alterna-
tively, nonpeptidic, small-molecule α-helix mimetics have at-
tracted significant interest. In general, small molecules are more
Significance
Many complex diseases are caused by aberrant protein–protein
interactions or protein misfolding, which present immense chal-
lenges for drug discovery. Here, we present the design, synthe-
sis, and usage of a diverse library of potential pharmacological
chaperones that could interfere with undesirable protein–protein
interactions and prevent aggregation of misfolded proteins.
Author contributions: M.O., Q.Q.H., and H.-S.L. designed research; M.O., J.H.L., W.W.,
H.S.L., W.S.L., C.B., and W.I. performed research; M.O., J.H.L., W.W., Q.Q.H., and H.-S.L.
analyzed data; and Q.Q.H. and H.-S.L. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
1M.O. and J.H.L. contributed equally to this work.
2Present address: New Drug Development Center, Daegu Gyeongbuk Medical Innovation
Foundation, Daegu 701-310, South Korea.
3To whom correspondence may be addressed. Email: hslim@postech.ac.kr or qqhoang@
iu.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1320556111/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1320556111 PNAS | July 29, 2014 | vol. 111 | no. 30 | 11007–11012
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
preferable over peptides for their cell permeability, proteolytic
resistance, and bioavailability. Hamilton and colleagues pio-
neered the development of nonpeptidic α-helix mimetics. They
demonstrated the proof of concept that appropriately function-
alized terphenyl 1 (Fig. 1B) can physically mimic α-helical
structures and functionally active as inhibitors of α-helix-medi-
ated PPIs (19). This pioneering work inspired considerable
efforts devoted to developing small-molecule α-helix mimetics
(18, 19). However, the majority of these efforts were stymied by
the relatively poor water solubility and synthetic difficulty of
α-helix mimetic molecules. To overcome this critical barrier,
we set out to develop α-helix mimetic scaffolds with greater
synthetic accessibility that yield products with favorable phy-
sicochemical properties.
To obtain such molecules, we designed a triazine-piperazine-
triazine scaffold 2 (Fig. 1C). This scaffold is composed of a pipera-
zine ring between two triazine rings. Piperazines are found in many
biologically active molecules and can be a good replacement of
a phenyl ring in terphenyl structures (30–32). Triazine is a widely
used privileged scaffold because of its broad range of biological
activities and ease of synthetic manipulation (33, 34). We used this
scaffold as the backbone and functionalized its R1, R2, and R3
groups to form α-helix mimetics. To determine the physical re-
semblance of peptide α-helices, we used in silico molecular dy-
namics simulation to generate and energy-minimize potential
rotamers of the scaffold with arbitrary functional groups. This
computational study predicted that spatial arrangements of the
three functional groups (R1, R2, and R3) precisely matched the
locations of side chains (i, i + 3 or i + 4, and i + 7) on peptidic
α-helices (Fig. 1D), suggesting our scaffold could mimic α-helical
structures with appropriate placement of side chains.
To gain insight into the properties of our scaffold in solution, we
determined its aqueous partition coefficient. The calculated log
Poctanol/water (Clog P) value for triazine-piperazine-triazine scaffold
2a is 1.36, which is within the desirable range of hydrophilicity.
This is a significant improvement over the current terphenyl
scaffold 1a, the Clog P of which is 6.21 (Fig. 1E), suggesting the
improved aqueous solubility of the triazine-piperazine-tri-
azine scaffold has more “drug-like” properties.
Moreover, in addition to three variable locations for side chain
mimetic functional groups (R1, R2, and R3), scaffold 2 also con-
tains two diversification sites (R4 and R5) for modulating its overall
hydrophilicity (Fig. 1C). Most biologically active helical peptides
are amphipathic, with one side containing hydrophobic residues
(usually at protein-contacting areas) and with hydrophilic residues
on the other side, which presumably improves solubility. Such he-
lical peptides bearing solvent-exposed hydrophilic surfaces are
energetically favorable when binding to a target protein. In addi-
tion, charged residues on amphipathic helical peptides often par-
ticipate in hydrophilic interactions with charged residues on the
protein surface, resulting in an additional contribution to
binding affinity and specificity (35). Surprisingly, among many
nonpeptidic small-molecule α-helix mimetics, there are only a few
amphiphilic α-helix mimetic scaffolds (31, 36–38). Given the two
additional sites (R4 and R5) on the opposite side, our scaffold 2 can
effectively mimic amphiphilic α-helical structures by introducing
various hydrophilic functional groups at R4 and R5, thereby po-
tentially leading to more potent and selective ligands.
Solid-Phase Synthesis. We have developed a concise, divergent
solid-phase synthetic route to prepare the triazine-piperazine-tri-
azine scaffold (SI Appendix, Scheme S1). First, monosubstituted
dichlorotriazines 3 were loaded onto Rink-Amide resin. 2-Nitro-
benzenesulfonyl-protected piperazine derivatives 5 were coupled to
the resin-bound triazine derivatives 4. After removing the N-nitro-
benzenesulfonyl protecting group on 6, 2-ethylamino-4,6-dichloro-
[1,3,5]triazine 7 was introduced to afford 8. The chloride was dis-
placed with various amines (R3R3′NH). Finally, cleavage reaction
with trifluoroacetic acid furnished trifunctionalized compounds 9.
To assess the feasibility of the solid-phase synthesis, a series of
compounds was prepared, using various building blocks. The purity
and identity of the released crude products were analyzed by liquid
chromatography/MS (SI Appendix, Figs. S1 and S2). The average
purity of the final products was >92%, demonstrating the efficiency
of our solid-phase synthesis. Compared with convergent, lengthy
solution-phase synthesis of most terphenyl-based structures, our
solid-phase synthetic route is simple and divergent, allowing for the
rapid creation of large numbers of diversely functionalized com-
pounds by using many readily available building blocks.
Peptoid-Encoded One-Bead-One-Compound Combinatorial Library.
Although many different HTS methods are available for tradi-
tional drug targets such as enzymes, there are limited numbers of
screening methods for detecting PPI regulators (20, 21). Indeed,
there are only a few reports on the use of HTS to identify α-helix
mimetic small molecules (39–41). The most frequently used
method to identify α-helix mimetics is a competitive binding
assay, using a fluorescence polarization (FP). This assay is de-
signed to find compounds that disrupt a pairwise interaction
between a target protein and a fluorescently labeled helical
peptide. However, such binding peptides do not always exist,
and identifying them is another challenge (especially when high-
resolution structural information for protein complexes is not
available). More importantly, this type of competitive assay may
not be suitable for detecting PPI stabilizers. Hence, development
of convenient HTS methods is of considerable interest for facili-
tating the identification of pharmacological chaperones.
Using our divergent solid-phase synthesis protocol, a large,
combinatorial library is readily accessible. For the rapid and ef-
ficient selection of best compounds among a library of α-helix
mimetics, we developed a convenient HTS method by taking
advantage of a bead-based screening platform, which was origi-
nally developed by Lam and colleagues for screening peptides
(42) and has been successfully applied to cyclic peptides and
peptidomimetics such as β-peptides and peptoids (29, 43–47).
Relative to conventional HTS assays, on-bead screening has
several advantages (48). This method enables a large number of
library molecules (literally more than millions) to be screened
simultaneously by incubating with a target protein in a single test
tube. In addition, bead-based screening does not require any
prior knowledge on structures of target proteins and binding
partners (either proteins or peptides). Importantly, many protein
surfaces often alter their conformation on binding with partner
proteins or ligands, creating new binding pockets (49). Such
dynamic pockets, induced by the adaptive nature of protein
Fig. 1. (A) α-Helix with i, i + 4, and i + 7 side-chain positions. (B) Terphenyl-
based α-helix mimetic scaffold 1. (C ) Triazine-piperazine-triazine-based
α-helix mimetic scaffold 2. (D) An energy-minimized structure of 2a (R1, R2,
R3 = CH3; R4, R5 = H) and overlay with α-helix. (E ) Comparison of Clog
P values of 1a and 2a.
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surfaces, are difficult to predict. In this context, unbiased
approaches through on-bead screening of a large one-bead one-
compound (OBOC) library could be a powerful tool for finding
compounds that induce and bind to such unpredictable binding
pockets on protein interfaces.
Inspired by Lam’s peptide-based encoding method (50), we
constructed a peptoid-encoded OBOC combinatorial library of
α-helix mimetics on topologically segregated bilayer beads (Fig.
2). Peptoids would offer several attractive features as coding
materials (44, 51): Peptoids can be efficiently synthesized under
very mild conditions (52–54), which would be compatible with
various reaction conditions used for synthesis of library mole-
cules, and in addition, a vast number of structurally diverse
primary amines, as the diversity-generating element in peptoid
synthesis, are readily available from commercial sources.
A peptoid-encoded combinatorial library was synthesized on
bifunctional beads, in which triazine-piperazine-triazines are
displayed on the outer layer of the beads, and peptoids as coding
tags are separately incorporated in the interior of the beads (SI
Appendix, Fig. S3). Therefore, only α-helix mimetics on the bead
surface can be exposed to a target protein during on-bead
screening, and the structure of hit compounds will be revealed by
sequencing the corresponding peptoids (Fig. 2). The diversity of
this OBOC combinatorial library was 18 × 3 × 27 = 1,458 (SI
Appendix, Figs. S3 and S4).
High-Throughput Screen Against MCL-1. To demonstrate the effi-
cacy of our peptoid-encoded OBOC library of α-helix mimetics,
MCL-1 was chosen as a target protein. MCL-1 is a member of
the antiapoptotic B-cell lymphoma 2 (BCL-2) family of proteins
that includes BCL-2, BCL-XL, Al, and BCL-w. BCL-2 proteins
interact with BCL-2 homology domain 3 (BH3) protein family
members such as BAK and block their apoptosis-inducing ac-
tivity, thereby promoting cell survival. Given the critical roles of
BCL-2 in cancer progression, inhibition of the PPIs between
BCL-2 prosurvival proteins and BH3 proapoptotic proteins is
emerging as an attractive strategy for cancer treatment (55).
Many efforts have been made to develop BH3 mimetics to dis-
rupt the BCL-2/BH3 interactions, which are mediated by binding
an α-helical peptide segment in BH3 into the hydrophobic cleft
of BCL-2 (55). One of the most potent BCL-2 inhibitors is ABT-
737 (56). Interestingly, ABT-737 binds to BCL-2 and BCL-XL
with high affinity, but not to MCL-1. Not surprisingly, ABT-737
is not effective in cancer cells overexpressing MCL-1 (57). Given
that overexpression of MCL-1 is observed in many cancers and
is associated with cancer progression and drug resistance, it is
generally accepted that inhibition of MCL-1, as well as BCL-2, is
a promising strategy for effective cancer treatment (58). Hence,
developing MCL-1 inhibitors (either MCL-1-specific inhibitors
to use in combination with current BCL-2 inhibitors or pan BCL-2
family inhibitors) is of considerable interest.
For selection of the best MCL-1 ligands from the library
molecules, we executed two rounds of on-bead screens, using
magnetic separation followed by alkaline phosphatase-based
detection (SI Appendix) (44, 47). Briefly, 25 mg (∼10,200 beads,
about seven copies of diversity) of the library beads were
screened for their binding ability to MCL-1ΔNΔC (amino acids
172–320), a BH3-binding domain of MCL-1, by incubating the
library beads with 200 nM biotinylated MCL-1ΔNΔC overnight
at 4 °C. After washing unbound protein, followed by exposure to
streptavidin-coupled Dynabeads (iron oxide particles), several
hundred positive beads were selected by magnetic separation.
These initial hit beads were again screened using 100 nM bio-
tinylated MCL-1ΔNΔC for 4 h at 4 °C, followed by probing with
streptavidin-conjugated alkaline phosphatase. After treatment
with 5-bromo-4-chloro-3-indolyl phosphate, a substrate for col-
orimetric detection of alkaline phosphatase, 10 blue-colored
beads were isolated as putative hits. Peptoids released from in-
dividual beads were sequenced by MS/MS (SI Appendix, Fig. S5).
Notably, the sequence analysis revealed that the 10 beads con-
tained identical peptoid sequences, falling into 3 kinds of pep-
toids; five of peptoid-1, three of peptoid-2, and two of peptoid-3
(SI Appendix, Fig. S6). Note that about seven copies of library
molecules were used in this screen. This result shows the ro-
bustness of our screening platform. The chemical structures of
the corresponding triazine-piperazine-triazines (9a–9c) were
unambiguously decoded by the coding peptoid sequences (Fig.
3A). For further studies, the hit compounds 9a–9c and their
fluorescently labeled derivatives 9a–9c-FL (Fig. 3A) were syn-
thesized (SI Appendix, Fig. S7) and purified by HPLC (SI Ap-
pendix, Figs. S8 and S9). Note that the compounds 9a–9c were
shown to be reasonably soluble in aqueous solution (∼100 μg/mL
in phosphate buffer saline at pH 7.4, which is within a range of
water solubility for the favorable oral absorption of drugs) (59).
MCL-1 Binding Assays. To validate the binding ability of the hit
compounds to MCL-1ΔNΔC, FP experiments were executed.
9a-FL, 9b-FL, and 9c-FL bound MCL-1ΔNΔC with KD values of
2.8, 3.0, and 1.1 μM, respectively. The binding affinity of a known
BH3 peptide (58) used as a positive control was 0.3 μM, which is
similar to the reported binding affinity (KD = 245 nM) (Fig. 3B).
To verify whether the fluorescein and linker conjugated to 9a–9c
have any effects on the binding between the compounds and MCL-
1ΔNΔC, we synthesized a fluorescein-linker moiety, Fluor-linker
(SI Appendix, Figs. S7 and S9), and used it as a negative control. As
shown in Fig. 3B, Fluor-linker did not exhibit any binding to MCL-
1ΔNΔC, showing that the fluorophore and the linker have no
contribution to the binding affinity of 9a–9c to MCL-1. We then
performed a competitive FP assay using nonlabeled compounds
9a–9c to determine whether they are able to antagonize the in-
teraction between MCL-1 and BH3 (Fig. 3C). As expected, 9b and
9c dissociated the MCL-1ΔNΔC/BH3 interaction with Ki values of
9.3 and 17.5 μM, respectively, whereas 9a had weak activity. 9-nc,
a negative control compound, did not bind to MCL-1ΔNΔC (Fig.
3C). We chose 9c for more detailed investigation because it has the
highest binding affinity among the three hits. To determine
whether 9c has selectivity for MCL-1 over other structurally similar
proteins, we used competitive FP assays to measure the binding
affinity of 9c against BCL-XLΔC (amino acids 1–212), which is
a deletion construct of human BCL-XL, another BCL-2 protein
member, with the BH3 binding pocket similar to MCL-1. We found
that 9c did not significantly inhibit the interaction between BCL-
XLΔC and a BH3 peptide (SI Appendix, Fig. S10), indicating that 9c
is selective for MCL-1. To understand how 9c might bind to
MCL-1ΔNΔC, we computationally docked 9c into the binding
site for BH3. The three functional groups at R1, R2, and R3 on the
Fig. 2. General strategy for the identification of α-helix mimetics that bind
to a target protein through on-bead screening of peptoid-encoded OBOC
library of α-helix mimetics.
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triazine-piperazine-triazine 9c make interactions with the hy-
drophobic groove on the surface of MCL-1, mimicking the
binding mode of the BH3 helical peptide (SI Appendix, Fig. S11).
MCL-1 Cellular Assays. To examine whether 9c is cell-permeable
and can disrupt native interactions between MCL-1 and proa-
poptotic proteins inside cells, we performed coimmunoprecipi-
tation experiments. Jurkat T cells were treated with DMSO as
a carrier control or increasing concentrations of 9c, and cell
lysates were immunoprecipitated with anti-MCL-1 antibody and
subjected to Western blot, using anti-BAK and anti-MCL-1
antibodies (Fig. 4A). The BAK Western blot analysis showed
that immunoprecipitated BAK was dose-dependently decreased
in 9c-treated cells. In contrast, 9-nc, a negative control, did not
inhibit the MCL-1/BAK interaction (SI Appendix, Fig. S12). This
result ensures that 9c is cell permeable and competitively binds
to MCL-1, liberating BAK protein. Cellular uptake of 9c was
confirmed using confocal microscopy (Fig. 4B).
Blocking the MCL-1/BH3 interaction by 9c would liberate
proapoptotic proteins such as BAK from MCL-1, resulting in
apoptosis induction and cell-growth inhibition. To test this, Jurkat
human leukemia T cells and human multiple myeloma U266 cells
were treated with DMSO or varying concentrations of 9c and 9-nc,
and cell viability was evaluated by MTS assays. Indeed, 9c killed
Jurkat T cells and U266 cells in a dose-dependent manner, but not
normal cells such as WS-1 human fibroblast cells and human
embryonic kidney (HEK) 293 cells (Fig. 4C and SI Appendix, Fig.
S13A), indicating it has selective toxicity to malignant cells with
MCL-1 overexpression over normal cells. 9-nc, a negative control,
had no significant effect on both cancerous cells and normal cells.
To validate whether the selective cytotoxicity of 9c is a result of
caspase-dependent apoptosis, we conducted apoptosis assays.
U266 cells and WS-1 cells were exposed to DMSO or various
concentrations of 9c, and caspase activity was monitored by Cas-
pase-Glo 3/7 assay kit. As expected, 9c induced caspase activation
in U266 cells, but not in WS-1 cells (SI Appendix, Fig. S13C).
As a consequence, we have successfully demonstrated that a cell-
permeable PPI inhibitor can be identified through on-bead
screening of a combinatorial library of α-helix mimetics. 9c can
be a starting point for development of potent inhibitors tar-
geting MCL-1. Further biological evaluation and structure–activity
relationship studies are currently in progress to obtain more
potent and selective MCL-1 inhibitors.
α-Synuclein Screening. To determine whether our compounds are
effective pharmacological chaperones in stabilizing protein folding
and/or preventing protein aggregation, we used α-synuclein as
a representative of protein-folding-related diseases. α-Synuclein
aggregation leading to the formation of Lewy bodies is the patho-
logical hallmark of Parkinson disease (60). The mechanism of
Lewy body formation is still unclear. However, various lines of
evidence indicate that misfolding of α-synuclein and subsequent
inappropriate self-association are key steps in Lewy body formation
(61). α-Synuclein was traditionally thought to be a natively unfolded
protein (62); however, recent evidence by our group and others
suggest it also exists as folded tetramers (63, 64), which implies that
destabilization of the tetramer might lead to more aggregation-
prone species. These findings opened venues for testing new ther-
apeutic approaches for this devastating disease for which there is no
cure and for which there are no effective treatments. Here, we use
our α-helix-mimetic compounds to test the approach of preventing
α-synuclein aggregation by stabilizing its folded structure and/or
preventing aberrant self-association with pharmacological chap-
erones. This is an ideal test case for our chemical library be-
cause α-synuclein consists mostly of α-helices (∼65%), and its
aggregation could be monitored in real-time (63, 64).
For the screening assay, we engineered a construct of α-synu-
clein consisting of an N-terminal extension MKCK quad-peptide
to introduce a reactive cysteine residue for chemical linking with
biotin (wild-type α-synuclein contains no cysteine). The cysteine-
containing α-synuclein (cys-Syn) was biotinylated (SI Appendix,
Fig. S14) and used for screening, as described earlier for MCL-1.
On-bead screening identified two hit compounds, Q1 and Q2,
as potential α-synuclein binders (Fig. 5A). We then synthesized
and purified these compounds for further experimentation (SI
Appendix, Fig. S9).
α-Synuclein Binding Assay. To confirm the binding of the hit
compounds, we used FP assay as described earlier for MCL-1.
Q1 and Q2 were found to bind to α-synuclein with KD values of
68 and 148 nM, respectively (Fig. 5B). Q1 and Q2 share two
identical side chains at R1 and R2 and similar features at R3,
Fig. 3. (A) Structures of hit compounds 9a–9c and a negative control 9-nc.
(B) Binding curves for 9a–9c binding to MCL-1. (C) Inhibition curves of 9a–9c
for fluorescein-labeled BH-3 peptide binding to MCL-1. Error bars represent
SD from three independent experiments.
Fig. 4. Cellular activity of 9c. (A) Coimmunoprecipitation assay. Jurkat T
cells were treated with DMSO or varying concentrations of 9c for 2.5 h. The
effect of 9c on the MCL-1/BH3 interaction was analyzed by MCL-1 immu-
noprecipitation and BAK western analysis. The results are representative of
three independent experiments. (B) Confocal microscopic images of A549
cells treated with 1 μM 9c-FL, or 5 (6)-carboxyfluorescein (Flu), for 4 h. (C)
Effect of 9c and 9-nc (a negative control) on cell viability of Jurkat T leu-
kemia cells (Left) and WS-1 normal fibroblast cells (Right).
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with both consisting of 1,2-dialkoxybenzene (Fig. 5A). To in-
vestigate the contributions of compound backbone and rophore
linker to the observed binding of Q1 and Q2 to α-synuclein, we
measured the binding of MCL-1 hit compounds 9a–9c, which
have the same backbone structure as Q1–Q2, and Fluor-linker.
As shown in Fig. 5B, 9a and 9b showed very weak binding, and
Fluor-linker did not show detectable binding. Compound 9c,
which contains two identical side chains as the Q compounds,
showed moderate affinity to α-synuclein, as anticipated. Con-
versely, we also examined whether α-synuclein-interacting com-
pounds bind to MCL-1. Consistent with the structural features,
Q1, which has similar structure to 9c, moderately inhibited MCL-
1/BH3 interactions, whereas Q2 showed little effect (SI Appendix,
Fig. S15). In the subsequent cell viability assay, bothQ1 andQ2 had
no significant effect on the viability of both cancerous leukemia cells
and normal cells (SI Appendix, Fig. S15). Taken together, these
results indicate that the binding and selectivity of the compounds
for their target proteins are conferred by the compounds’ side
chains. To further confirm the binding of Q compounds and their
effects on α-synuclein thermal stability, we used circular dichroism
thermal stability assay. As shown in Fig. 5C and SI Appendix, Fig.
S16, Q1 and Q2 shifted the melting temperature of α-synuclein
from 37 °C to 40 °C and 41 °C, respectively. The α-helices on
α-synuclein are amphiphilic, with long stretches of hydrophobic
surfaces (64, 65); the relatively hydrophobic Q1 and Q2 probably
interact with the hydrophobic surfaces on α-synuclein. How the
binding of these compounds affects the structure of α-synuclein
warrants further investigation; however, our objectives here are to
test whether our library consists of molecules that could bind and
inhibit α-synuclein aggregation, which is detailed here.
α-Synuclein Aggregation Assay. On the basis of the confirmed
binding affinity of Q1 and Q2 to α-synuclein, we set out to de-
termine whether the binding of Q1 and Q2 affects the aggregation
propensity of α-synuclein. As mentioned earlier, we initially
screened for Q-compounds using wild-type α-synuclein; however,
the wild-type does not aggregate readily, so we used an aggrega-
tion-prone, disease-associated mutant (A53T) to perform aggre-
gation assays. To ascertain that Q1 and Q2 also bind to A53T, we
repeated the FP binding assay using A53T protein and we found
thatQ1 andQ2 also bind strongly to the A53T mutant (KD values =
268 and 372 nM, respectively), albeit at slightly lower affinity
compared with wild-type α-synuclein (Fig. 6A). Compounds 9a–
9c also showed similar binding patterns as those observed with
wild-type α-synuclein. We selected 9a as a negative control for
aggregation assays because it showed no binding to α-synuclein.
We preincubated Q1, Q2, 9a, and DMSO with A53T mutant
α-synuclein and monitored its aggregation using Thioflavin-T fluo-
rescence aggregation assay, as previously described (64). We found
that both Q1 and Q2 significantly delayed the onset of aggregation
and dramatically decreased the total amounts of aggregated fibrils
within the30-hdurationofourexperiment (Fig. 6B),whereasDMSO
and 9a did not inhibit aggregation of A53T mutant α-synuclein.
Although the mechanisms by which the Q-compounds prevent
α-synuclein aggregation are still unclear, it is consistent with the
idea that the binding of Q1 and Q2 to α-synuclein prevented it
from aggregating, either by masking the surfaces that directly
involve in aggregation or by preventing its conversion/misfolding
into aggregation prone species. In any case, our data demonstrate
that our chemical library consists of molecules that effectively
inhibited α-synuclein fibrillation and suggests these compounds
might be useful also for other proteins associated with protein-
misfolding and aggregation-prone related diseases.
Conclusions
Despite their great potential as therapeutic candidates for the
treatment of many diseases caused by protein instability and/or
aberrant protein–protein interactions, discovering pharmacological
chaperones for specific target proteins is among the most difficult
challenges in drug discovery and chemical biology. Here, we have
presented an approach that allows for large-scale synthesis of a
peptoid-encoded OBOC combinatorial library of α-helix mimetic
small molecules and rapid identification of potential pharmaco-
logical chaperones through a facile “on-bead” HTS. The proof-of-
concept screens against a cancer-associated protein MCL-1 and a
Parkinson disease-associated protein α-synuclein demonstrated
that that triazine-piperazine-triazine-based α-helix mimetics are
effective at binding and modulating the activity and behavior of
distinctly different helical proteins. MCL-1 is an established ca-
nonical helical protein that interacts with other helical struc-
tures, suggesting that the hit compounds that we identified likely
mimicked certain features of MCL-1’s natural binding partners.
α-Synuclein, in contrast, has no known structures; its interacting
partners are unknown (aside from self-associating), and aggrega-
tion mechanism is still a mystery. What we do know is that when
partially folded, it consists of dynamic helical structures, thus
demonstrating that our method is capable of obtaining hit com-
pounds even without prior knowledge of the structure of the target
protein or its binding partners. Given the convenience of the
screening method and structural diversity of the library, we believe
our strategy could be a useful approach to developing pharmaco-
logical chaperones against a wide range of different helical proteins.
Fig. 5. (A) Structure of Q1 and Q2, hit compounds to α-synuclein. (B) FP
assays. Binding affinity of hit compounds Q1, Q2, negative controls 9a–9c,
and Fluro-linker against wild-type α-synuclein were determined using FP
assay. (C) Circular dichroism thermal denaturation assay. Unfolding of
α-synuclein in the presence or the absence of hit compounds Q1 and Q2
were monitored using ellipticity at 222 nm, with respect to temperature.
Fig. 6. (A) FP assays. Binding affinity of Q1, Q2, 9a–9c, and Fluor-linker
against the disease-associated mutant of α-synuclein A53T were measured
using FP assay. (B) Thioflavin-T aggregation assays. Effects of Q1, Q2, and
negative-control 9a on aggregation of α-synuclein A53T were determined by
using Thioflavin-T fluorescence aggregation assay.
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Methods
Synthesis and characterization of 9a–9c and Q1–Q2 can be found in SI
Appendix. Protocols for OBOC library synthesis and on-bead screening are
detailed in SI Appendix. Methods of molecular docking, protein purifi-
cation, binding assays, cell viability assays, caspase assays, confocal mi-
croscopy experiment, coimmunoprecipitation assays, circular dichroism
thermal stability assay, and thioflavin-T aggregation assay are described
in SI Appendix.
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